Activity Overview
Intravitreal anti-VEGF therapies are the standard of care for retinal conditions, including neovascular age-related macular degeneration and diabetic macular edema. However, injections may be associated with potentially serious adverse events (AEs). In this second episode of a 6-part series, an expert faculty member shares clinical trial and real-world data on these AEs and insights into their prevention and management.
Target Audience
This educational curriculum is directed toward retina specialists and ophthalmologists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the safety profile of next-generation anti-VEGF therapies, including rates and management of intraocular inflammation, intraocular pressure elevation, and injection-related AEs
- Implement evidence-based monitoring protocols for patients receiving durable, next-generation anti-VEGF injections
Hong-Uyen Hua, MD
Assistant Professor of Clinical Ophthalmology
Adult & Pediatric Retina
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Alcon, ANI, Apellis, EyePoint; Speaker’s Bureau: Amgen
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.